CLRB

Cellectar Biosciences, Inc. (CLRB) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary Phospholipid Drug Conjugate (PDC) platform. The Company is primarily advancing iopofosine I 131 for Waldenstrom macroglobulinemia (WM), alongside programs for CLR 125 (triple-negative breast cancer) and CLR 225 (solid tumors). As of June 30, 2026, the Company had 9,452,108 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Liquidity Improvement: Cash and cash equivalents increased significantly from $13.20 million at year-end 2025 to $33.99 million at June 30, 2026. This was driven by a May 2026 financing transaction raising approximately $31.7 million in net proceeds.
• Equity Structure: All outstanding Series D and Series E-2 preferred stock were converted into common stock during the period. The Company also issued common stock, pre-funded warrants, and milestone-based warrants in the May 2026 offering.
• Expense Trends:
  • R&D: Increased 30% year-over-year (YTD) to $7.56 million, primarily due to the initiation of the Phase 3 confirmatory study for iopofosine I 131 and the Phase 1b study for CLR 125.
  • G&A: Decreased 18% year-over-year (YTD) to $5.43 million, driven by reduced professional fees and personnel costs.
• Warrant Liability: The fair value of liability-classified warrants decreased from $226,000 at year-end 2025 to $17,000 at June 30, 2026, resulting in a non-cash gain of $209,000 included in other income.

Guidance, Outlook, and Risks

• Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern. Management estimates available liquidity of approximately $29 million (unrestricted cash) as of the issuance date, which may be insufficient to fund operations beyond the second quarter of 2027 without additional capital.
• Regulatory Strategy: The Company is preparing to submit a New Drug Application (NDA) for accelerated approval of iopofosine I 131 for WM, contingent upon the initiation of a Phase 3 confirmatory study. The Phase 3 study was initiated in June 2026.
• Financing: The May 2026 offering included milestone-based securities (up to $105 million) tied to regulatory and clinical milestones (e.g., Phase 3 initiation, NDA acceptance, FDA approval).
• Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding the accounting for preferred equity, warrants, stock-based compensation, and fair value methodologies. Disclosure controls and procedures were deemed ineffective.
• Risks: Key risks include failure to obtain regulatory approval, inability to raise additional capital, and the potential need to seek strategic alternatives (mergers, asset sales, or bankruptcy) if liquidity plans fail.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $29 million cash balance against the projected burn rate for the Phase 3 study and ongoing operations.
• Warrant Terms: Review the specific milestones and exercise prices for the Tranche A, B, and C warrants issued in May 2026, as these represent significant potential dilution.
• Internal Control Remediation: Assess the timeline and effectiveness of the plan to remediate the identified material weaknesses in financial reporting.
• Phase 3 Enrollment: Monitor the progress of patient enrollment in the Phase 3 confirmatory study for iopofosine I 131, as this is a critical predicate for NDA submission.
• Preferred Stock Conversion: Confirm the final share count and dilution impact resulting from the conversion of all Series D and E-2 preferred stock.